These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 34588184)
1. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. Van Praet J; Reynders M; De Bacquer D; Viaene L; Schoutteten MK; Caluwé R; Doubel P; Heylen L; De Bel AV; Van Vlem B; Steensels D; De Vriese AS J Am Soc Nephrol; 2021 Dec; 32(12):3208-3220. PubMed ID: 34588184 [TBL] [Abstract][Full Text] [Related]
2. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364 [TBL] [Abstract][Full Text] [Related]
3. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E Front Immunol; 2022; 13():907615. PubMed ID: 35812459 [TBL] [Abstract][Full Text] [Related]
4. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811 [TBL] [Abstract][Full Text] [Related]
5. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719 [TBL] [Abstract][Full Text] [Related]
6. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800 [TBL] [Abstract][Full Text] [Related]
7. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination. Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J Front Immunol; 2022; 13():845882. PubMed ID: 35401504 [TBL] [Abstract][Full Text] [Related]
8. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days. Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R Front Immunol; 2021; 12():726960. PubMed ID: 34671348 [TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children. Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243 [TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered. López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A Front Immunol; 2023; 14():1129753. PubMed ID: 37006309 [TBL] [Abstract][Full Text] [Related]
11. 25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations. Lavell AHA; Schramade AE; Sikkens JJ; van der Straten K; van Dort KA; Slim MA; Appelman B; van Vught LA; Vlaar APJ; Kootstra NA; van Gils MJ; Smulders YM; de Jongh RT; Bomers MK; Vaccine; 2024 Mar; 42(7):1478-1486. PubMed ID: 37775466 [TBL] [Abstract][Full Text] [Related]
12. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
13. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients. Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Van Biesen W; Jacques P; Verhasselt B; Padalko E Front Immunol; 2022; 13():858399. PubMed ID: 35401575 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos C; Lucas C; Macario F; Haase M J Nephrol; 2021 Aug; 34(4):975-983. PubMed ID: 34050904 [TBL] [Abstract][Full Text] [Related]
17. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083 [TBL] [Abstract][Full Text] [Related]
18. Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients. Aoun M; Kahwaji RM; Sleilaty G; Boueri C; Hawi J; Khalil CB; Hage V Adv Clin Exp Med; 2022 Aug; 31(8):855-861. PubMed ID: 35438849 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. El Karoui K; De Vriese AS Kidney Int; 2022 May; 101(5):883-894. PubMed ID: 35176326 [TBL] [Abstract][Full Text] [Related]
20. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K Front Immunol; 2021; 12():704773. PubMed ID: 34220867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]